Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that additional analyses from the Phase 3 NAPOLI-1 study of MM-398 (nanoliposomal irinotecan injection), also known as "nal-IRI," in metastatic pancreatic cancer will be presented at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI), January 15-17, 2015 at Moscone West Building in San Francisco, CA. The data will be presented by Li-Tzong Chen, M.D., Ph.D., Director, Investigator and Attending Physician at the National Institute of Cancer Research in Taiwan.

Merrimack will also be presenting preclinical and clinical data supporting the development of MM-141 in combination with gemcitabine and nab-paclitaxel in front-line pancreatic cancer, as well as updated clinical and biomarker data from a Phase 1 trial of MM-151.

Oral Presentation

• Expanded analyses of NAPOLI-1: Phase 3 study of MM-398 (nal-IRI), with or without fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) patients previously treated with gemcitabine-based therapy (Abstract #234, Board A5)

Oral Abstract Session: Cancers Of The Pancreas, Small Bowel, And Hepatobiliary Tract
Friday, January 16, 2015, 2:00 p.m. PT
Li-Tzong Chen, M.D., Ph.D., Director, Investigator and Attending Physician at the National Institute of Cancer Research in Taiwan
Poster viewing time: Friday, January 16, 2015, 12:00-2:00 p.m. and 5:30-7:00 p.m. PT

Poster Sessions

• Session Title: General Poster Session B and Trials in Progress Poster Session B: Cancers Of The Pancreas, Small Bowel, And Hepatobiliary Tract
  Friday, January 16, 2015, 12:00-2:00 p.m. and 5:30-7:00 p.m. PT
  
  
  • Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation (Abstract #289, Board B10)
    
    
  • HER3 as a potential prognostic biomarker in pancreatic cancer (Abstract #295, Board B16)
    
    
  • First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3 (Abstract #384, Board D3)
    
    
• Session Title: General Poster Session C and Trials in Progress Session C: Cancers Of The Colon, Rectum, And Anus
  Saturday, January 17, 2015, 7:00-7:55 a.m. and 12:00-2:00 p.m. PT
  
  
  • Safety, pharmacology and preliminary clinical activity of MM-151: an oligoclonal anti-EGFR therapeutic in patients with cetuximab-resistant CRC and other refractory solid tumors (Abstract 647, Board C39)
    
    
  • PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer – A GERCOR study (Abstract 751, Board E41)

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and multiple candidates in preclinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.